Boehringer Ingelheim Venture Fund has co-led a $21.8m round for ImCheck Therapeutics, which announced its new CEO in conjunction with the funding.

Cambridge Enterprise and Cambridge Innovation Capital both participated in the funding round, which is based on research at the Cambridge Institute for Medical Research.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the NTNU spinout outright for about $180m more.

Exploiting research conducted at Navarra University and Harvard Medical School, Vivet Therapeutics is working on gene therapies for metabolic diseases.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the company outright for about $180m more.

France-based venture firm Elaia Partners has reached the first close of its fourth fund, with EDF, Nexity, ADP and Mgen all contributing capital.

The Paris-Saclay Seed Fund has participated in a funding round for Damae Medical, which has developed technology to detect skin cancer without the need for biopsies.

Future Planet Capital was among the investors that added an undisclosed sum to the $10m in series B funding Congenica raised in February.

BGI Genomics and Healthlink were among the investors that added an undisclosed sum to the $10m in series B funding Congenica raised in February.